Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Zinchenko (Saint-Petersburg, Russian Federation), L. Novikova (Saint-Petersburg, Russian Federation), M. Ilkovich (Saint-Petersburg, Russian Federation). Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up. 2142

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis Source: ERJ Open Res, 4 (1) 00089-2017; 10.1183/23120541.00089-2017 Year: 2018 Chemotherapy in patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018 Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019 Multisystemic Langerhans cell histiocytosis unresponsive to aggressive chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006 Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients Source: Eur Respir Rev 2013; 22: 93-95 Year: 2013 Exercise in patients with pulmonary Langerhans cell histiocytosis: performance and mechanisms of limitation Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Clinical study of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Cladribine improves lung cysts and pulmonary function in a child with histiocytosis Source: Eur Respir J 2015; 45: 831-833 Year: 2015 Langerhans' cell histiocytosis: clinical and diagnostic features and response to therapy Source: Eur Respir J 2001; 18: Suppl. 33, 219s Year: 2001 Long-term follow-up of patients with pulmonary sarcoidosis Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Clinical course and outcome of pulmonary Langerhans‘-cell histiocytosis Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Psychological abnormalities are commonly present in adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 Long-term treatment with infliximab in patients with sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Long-term response to prednisone in newly treated patients with pulmonary sarcoidosis Source: Virtual Congress 2021 – Better understanding of sarcoidosis: new keys Year: 2021 Treatment of pulmonary Langerhans cell histiocytosis with multifocal involvement with vinblastine, prednisolon, mercaptopurine Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 How I manage pulmonary Langerhans cell histiocytosis Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017 Year: 2017 The use of plasmapheresis in the treatment of patients with IY stage of pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 Smoking status and long term clinical outcome in patients with pulmonary Langerhans cell histiocytosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013